Quality of life issues in psoriasis

  • Amanda B. Sergay
  • Matthew Silvan
  • Jeffrey M. Weinberg
Part of the Milestones in Drug Therapy book series (MDT)


Health-related quality of life (HRQOL), has been defined as “peoples’ subjective evaluation of the influences of their current health status... on their ability to achieve and maintain a level of overall functioning that allows them to pursue valued life goals and that is reflected in general wellbeing” [1, 2]. Psoriasis is a chronic disease with physical, psychosocial, and economic implications that commonly interfere with patients’ daily functional capacity, and consequently, their quality of life.


Atopic Dermatitis Psoriatic Arthritis Psoriasis Patient Dermatology Life Quality Index Severe Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psorasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41: 401–407PubMedCrossRefGoogle Scholar
  2. 2.
    Shumaker SA, Naughton MJ (1995) The international assessment of health-related quality of life. In: RA Shumaker, R Berzon (eds): The international assessment of health-related quality of life theory, translation, measurement, and analysis. Rapid Communications; New York, 3–10Google Scholar
  3. 3.
  4. 4.
    Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE (2001) Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 45(1): 72–76PubMedCrossRefGoogle Scholar
  5. 5.
    Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsso B (2002) Epidemiology and Health Services Research: Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 146: 1006–1016PubMedCrossRefGoogle Scholar
  6. 6.
    Finlay AY, Ortonne JP (2004) Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cut Med Surg 8: 310–320CrossRefGoogle Scholar
  7. 7.
    Mease PJ, Menter MA (2006) Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54: 685–704PubMedCrossRefGoogle Scholar
  8. 8.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T (2006) Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 54: S101–111PubMedCrossRefGoogle Scholar
  9. 9.
    Fortune, DG, Richards HL, Griffiths CEM (2005) Pyschological factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 23: 681–694PubMedCrossRefGoogle Scholar
  10. 10.
    Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T (2001) The impact of psoriasis on quality of life: results of a 1998 National Psorasis Foundation patient-membership survey. Arch Dermatol 137: 280–284PubMedGoogle Scholar
  11. 11.
  12. 12.
    Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schafer G (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155: 729–736PubMedCrossRefGoogle Scholar
  13. 13.
    Yosipovitch G, Tang MBY (2000) Practical management of psoriasis in the elderly. Drugs Aging 19(11): 847–863CrossRefGoogle Scholar
  14. 14.
    Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50: 24–35PubMedCrossRefGoogle Scholar
  15. 15.
    De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC (1996) Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1’728 patients. Dermatology 193: 300–303PubMedCrossRefGoogle Scholar
  16. 16.
    Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR (2003) Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 49: 271–275PubMedCrossRefGoogle Scholar
  17. 17.
  18. 18.
    Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR (2006) The negative impact of psoriasis on the workplace. J Dermatolog Treat 17(1): 24–28PubMedCrossRefGoogle Scholar
  19. 19.
    Finlay AY, Coles E (1995) The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132: 236–244PubMedCrossRefGoogle Scholar
  20. 20.
    Schmitt JM, Ford DE (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213(2): 102–110PubMedCrossRefGoogle Scholar
  21. 21.
    Marchetti A, LaPensee K, An P (1998) A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clinical Therapy 20(4): 8518–8569CrossRefGoogle Scholar
  22. 22.
    Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S (2006) An Italian study on psoriasis and depression. Dermatology 212(2): 123–127PubMedCrossRefGoogle Scholar
  23. 23.
    Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P (2000) Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 143: 983–991PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta MA, Gupta AK (1998) Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139: 846–850PubMedCrossRefGoogle Scholar
  25. 25.
    Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A (2000) The depression, anxiety and life satisfaction and affective expression level in psoriasis patients. J Eur Acad Deramtol Venereol 14: 267–271CrossRefGoogle Scholar
  26. 26.
    Gupta MA, Gupta AK (1999) Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis and chronic idiopathic urticaria. Ann NY Acad Sci 885: 394–395PubMedGoogle Scholar
  27. 27.
    Gupta MA, Gupta AK, Watteel GN (1998) Perceived deprivation of social touch in psoriasis associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 61: 339–342PubMedGoogle Scholar
  28. 28.
    Richards HL, Fortune DG, Griffiths CE, Main CJ (2001) The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res 50: 11–15PubMedCrossRefGoogle Scholar
  29. 29.
    Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE (1997) Quality of life in psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 137: 755–760PubMedCrossRefGoogle Scholar
  30. 30.
    Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE (1997) Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 42: 467–476PubMedCrossRefGoogle Scholar
  31. 31.
    Fortune DG, Richards HL, Kirby B, McElhone K, Markham T, Rogers S, Main CJ, Griffiths CE (2003) Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139: 752–756PubMedCrossRefGoogle Scholar
  32. 32.
    Vardy D, Besser A, Amir M, Gesthalter B, Biton A, Buskila D (2002) Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 147: 736–742PubMedCrossRefGoogle Scholar
  33. 33.
    Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D (2003) The impact of skin diseases on patients: comparing dermatologists’ opinions with research data collected on their patients. Br J Dermatol 148: 989–995PubMedCrossRefGoogle Scholar
  34. 34.
    Gupta MA, Gupta AK (1995) Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol 34: 700–703PubMedCrossRefGoogle Scholar
  35. 35.
    Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D (2006) Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 154: 325–331PubMedCrossRefGoogle Scholar
  36. 36.
    Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC (2000) Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol 80: 272–276PubMedCrossRefGoogle Scholar
  37. 37.
    Schmid-Ott G, Kunsebeck HW, Jager B, Sittig U, Hofste N, Ott R, Malewski P, Lamprecht F (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1): 27–32PubMedCrossRefGoogle Scholar
  38. 38.
    Ginsburg IH (1996) The psychosocial impact of skin disease. Dermatol Clin 14: 473–484PubMedCrossRefGoogle Scholar
  39. 39.
    Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Psychodermatology 14: 485–496Google Scholar
  40. 40.
    Wahl A, Moum T, Hanestad BR, Wiklund I (1999) The relationship between demographic and clinical variables and quality of life aspects in patients with psoriasis. Qual Life Res 8: 319–326PubMedCrossRefGoogle Scholar
  41. 41.
    Higgins E (2000) Alcohol, smoking and psoriasis. Clin Exp Dermatol 25: 108–110CrossRefGoogle Scholar
  42. 42.
    Unaeze J, Nijsten T, Murphy A, Ravichandran C, Stern RS (2006) Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 126: 1480–1489PubMedCrossRefGoogle Scholar
  43. 43.
    Ellis CN, Mordin MM, Adler EY (2003) Effects of Alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 4: 131–139PubMedCrossRefGoogle Scholar
  44. 44.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A (2005) Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153: 1192–1199PubMedCrossRefGoogle Scholar
  45. 45.
    Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T (2006) Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 54: S101–111PubMedCrossRefGoogle Scholar
  46. 46.
    Krueger G, Wooley JM, Zitnik R (2004) The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis. Presented at the 62nd annual meeting of The American Academy of Dermatology, 6–11 Feb 2004, Washington D.C.Google Scholar
  47. 47.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349: 2014–2022PubMedCrossRefGoogle Scholar
  48. 48.
    Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A (2005) Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 53(5): 887–889PubMedCrossRefGoogle Scholar
  49. 49.
    Feldman SR, Menter A, Koo JY (2004) Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 150: 317–326PubMedCrossRefGoogle Scholar
  50. 50.
    Ortonne J, Shear N, Shumack S, Henninger E (2005) Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatology 5: 13PubMedCrossRefGoogle Scholar
  51. 51.
    Koo JY, Kowalksi J, Guenther L, Walker P (2004) Quality of life effect of oral tazarotene in patients with moderate to severe psoriasis as measured by the 12-item psoriasis quality of life questionnaire (PQOL-12). Presented at the 62nd annual meeting of the American Academy of Dermatology; 6–11 Feb 2004, Washington D.C.Google Scholar
  52. 52.
    Lim C, Brown P (2006) Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. Australas J Dermatol 47(1): 37–40PubMedCrossRefGoogle Scholar
  53. 53.
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939–1950PubMedCrossRefGoogle Scholar
  54. 54.
    Salek MS, Finlay AY, Lewis JJ, Sumner MI (2004) Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin (Neoral.) Qual Life Res 13: 91–95PubMedCrossRefGoogle Scholar
  55. 55.
    Bhosle MJ, Kulkarni A, Feldman S, Balkrishnan R (2006) Quality of life in patients with psoriasis. Health and Quality of Life Outcomes 4: 35PubMedCrossRefGoogle Scholar
  56. 56.
    Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349: 658–665PubMedCrossRefGoogle Scholar
  57. 57.
    Gottlieb AB, Ford RO, Spellman MC (2003) The efficacy and tolerability of clobetasol proprionate foam 0.05% in the treatment of mild to moderate plaque type psoriasis in nonscalp regions. J Cutan Med Surg 7: 185–192PubMedGoogle Scholar
  58. 58.
    Gupta MA, Gupta AK (2001) The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 15: 512–518PubMedCrossRefGoogle Scholar
  59. 59.
    Zaghloul SS, Goodfield MJ (2004) Objective Assessment of compliance with psoriasis treatment. Arch Dermatol 104: 408–414CrossRefGoogle Scholar
  60. 60.
    David SE, Ahmed Z, Salek MS, Finlay AY (2005) Does enough quality of life-related discussion occur during dermatology outpatient consultations? Br J Dermatol 153: 997–1000PubMedCrossRefGoogle Scholar
  61. 61.
    Feldman S, Behnam S, Behnam S, Koo JY (2005) Involving the patient: Impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol 53: S78–85PubMedCrossRefGoogle Scholar
  62. 62.
    Lu Y, Duller P, van der Valk PGM, Kraaimaat FW, van de Kerkhof PC (2003) Helplessness as predictor of perceived stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom 4: 146–150CrossRefGoogle Scholar
  63. 63.
    de Korte J, van Onselen J, Kownacki S (2005) Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J EurAcad Dermatol Venereol 19(1): 35–41CrossRefGoogle Scholar
  64. 64.
  65. 65.
    Gordon K (2005) Patient education and advocacy Groups. Arch Dermatol (141): 80–81PubMedCrossRefGoogle Scholar
  66. 66.
    Nijsten T, Rolstad T, Feldman SR, Stern RS (2005) Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 141: 19–26PubMedCrossRefGoogle Scholar
  67. 67.
    Jankowiak B, Krajewska-Kulak E, Baranowska A (2005) The importance of the health education in life quality improvement in patients with psoriasis. Rocz Akad Med Bialmyst 50Suppl 1: 145–147Google Scholar
  68. 68.
    Fortune DG, Richards HL, Main CJ, Bowcock S, Main CJ, Griffiths CE (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146: 458–465PubMedCrossRefGoogle Scholar
  69. 69.
    Price, ML, Mottahedin I, Mayo PR (1991) Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 16(2): 114–117PubMedCrossRefGoogle Scholar
  70. 70.
    Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf M, Cropley T, Hosmer D, Bernhard J (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergong phototherapy (UVB) and photochemotherapy (PUVA). Psychosomatic Med 60: 625–632Google Scholar
  71. 71.
    Koblenzer CS (1987) Psychocutaneous disease. Grune and Stratton, Orlando, Florida, USGoogle Scholar
  72. 72.
    Britten N, Stevenson FA, Barry CA, Barber N, Bradley CP (2000) Misunderstandings in prescribing decisions in general practice: qualitative study. BMJ 320: 484–488PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Amanda B. Sergay
    • 1
  • Matthew Silvan
    • 1
  • Jeffrey M. Weinberg
    • 1
  1. 1.Department of DermatologySt. Luke’s-Roosevelt Hospital Center and Beth Israel Medical CenterNew YorkUSA

Personalised recommendations